Ankush Bhatia

Ankush Bhatia

Auto-generated profile, based on publicly available information

Ankush Bhatia

Department of Neurology, Memorial Sloan Kettering Cancer Center, New York, New York

Research Focus & Metrics

Academic Career Length

20Years (2007-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2007 in Neurobiology of Disease
Verified
Journal Article
Closed access
CZChaohui Zhao
Chaohui Zhao
ZLZaodung Ling
Zaodung Ling
MNMary B. Newman
Mary B. Newman
ABAnkush Bhatia
Ankush Bhatia
PCPaul M. Carvey
Paul M. Carvey

17 October 2019 in Neuro-Oncology
Verified
Journal Article
Closed access
ABAnkush Bhatia
Ankush Bhatia
MBMaxwell Birger
Maxwell Birger
HVHarini Veeraraghavan
Harini Veeraraghavan
HUHyemin Um
Hyemin Um
FTFlorent Tixier
Florent Tixier
RYRobert J Young
Robert J Young
Background: Melanoma brain metastases historically portend a dismal prognosis, but recent advances in immune checkpoint inhibitors (ICIs) have been associated with durable responses in some patients. There are no validated imaging biomarkers associated with outcomes in patients with melanoma brain metastases receiving ICIs. We hypothesized that radiomic analysis of magnetic resonance images (MRIs) could identify higher-order features associated with survival.Methods: Between 2010 and 2019, we retrospectively reviewed patients with melanoma brain metastases who received ICI. After volumes of interest were drawn, several texture and edge descriptors, including first-order, Haralick, Gabor, Sobel, and Laplacian of Gaussian (LoG) features were extracted. Progression was determined using Response Assessment in Neuro-Oncology Brain Metastases. Univariate Cox regression was performed for each radiomic feature with adjustment for multiple comparisons followed by Lasso regression and multivariate analysis.Results: Eighty-eight patients with 196 total brain metastases were identified. Median age was 63.5 years (range, 19–91 y). Ninety percent of patients had Eastern Cooperative Oncology Group performance status of 0 or 1 and 35% had elevated lactate dehydrogenase. Sixty-three patients (72%) received ipilimumab, 11 patients (13%) received programmed cell death protein 1 blockade, and 14 patients (16%) received nivolumab plus ipilimumab. Multiple features were associated with increased overall survival (OS), and LoG edge features best explained the variation in outcome (hazard ratio: 0.68, P = 0.001). In multivariate analysis, a similar trend with LoG was seen, but no longer significant with OS. Findings were confirmed in an independent cohort.Conclusion: Higher-order MRI radiomic features in patients with melanoma brain metastases receiving ICI were associated with a trend toward improved OS.

7 July 2020 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ABAnkush Bhatia
Ankush Bhatia
VHVaios Hatzoglou
Vaios Hatzoglou
GUGary Ulaner
Gary Ulaner
RRRaajit Rampal
Raajit Rampal
DHDavid M Hyman
David M Hyman
EDEli L. Diamond
Eli L. Diamond
Erdheim–Chester disease (ECD) is a rare histiocytic neoplasm characterized by recurrent alterations in the MAPK (mitogen-activating protein kinase) pathway. The existing literature about the neuro-oncological spectrum of ECD is limited. We present retrospective clinical, radiographic, pathologic, molecular, and treatment data from 30 patients with ECD neurohistiocytic involvement treated at a tertiary center. Median age was 52 years (range, 7–77), and 20 (67%) patients were male. Presenting symptoms included ataxia in 19 patients (63%), dysarthria in 14 (47%), diabetes insipidus in 12 (40%), cognitive impairment in 10 (33%), and bulbar affect in 9 (30%). Neurosurgical biopsy specimens in 8 patients demonstrated varied morphologic findings often uncharacteristic of typical ECD lesions. Molecular analysis revealed mutations in BRAF (18 patients), MAP2K1 (5), RAS isoforms (2), and 2 fusions involving BRAF and ALK. Conventional therapies (corticosteroids, immunosuppressants, interferon-alpha [IFN-α], cytotoxic chemotherapy) led to partial radiographic response in 8/40 patients (20%) by MRI with no complete responses, partial metabolic response in 4/16 (25%), and complete metabolic response in 1/16 (6%) by 18F-fluorodeoxyglucose (FDG)-PET scan. In comparison, targeted (kinase inhibitor) therapies yielded partial radiographic response in 10/27 (37%) and complete radiographic response in 14/27 (52%) by MRI, and partial metabolic response in 6/25 (24%) and complete metabolic response in 17/25 (68%) by FDG-PET scan. These data highlight underrecognized symptomatology, heterogeneous neuropathology, and robust responses to targeted therapies across the mutational spectrum in ECD patients with neurological involvement, particularly when conventional therapies have failed.

25 January 2021 in Current Oncology Reports
Verified
Journal Article
Closed access
PDF file
ADAntonio Dono
Antonio Dono
LBLeomar Y Ballester
Leomar Y Ballester
DPDitte Primdahl
Ditte Primdahl
YEYoshua Esquenazi
Yoshua Esquenazi
ABAnkush Bhatia
Ankush Bhatia

22 February 2018 in Haematologica
Verified
Journal Article
Closed access
PDF file
ABAnkush Bhatia
Ankush Bhatia
GUGary Ulaner
Gary Ulaner
RRRaajit Rampal
Raajit Rampal
DHDavid M. Hyman
David M. Hyman
OAOmar Abdel-Wahab
Omar Abdel-Wahab
EDEli L. Diamond
Eli L. Diamond

1 November 2023 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
ABAnkush Bhatia
Ankush Bhatia
RMRaquel Moreno
Raquel Moreno
ARAnne S. Reiner
Anne S. Reiner
SNSubhiksha Nandakumar
Subhiksha Nandakumar
HWHenry S. Walch
Henry S. Walch
RYRobert J. Young
Robert J. Young
Purpose: Isocitrate dehydrogenase–mutant (IDH-mt) gliomas are incurable primary brain tumors characterized by a slow-growing phase over several years followed by a rapid-growing malignant phase. We hypothesized that tumor volume growth rate (TVGR) on MRI may act as an earlier measure of clinical benefit during the active surveillance period. Experimental Design: We integrated three-dimensional volumetric measurements with clinical, radiologic, and molecular data in a retrospective cohort of IDH-mt gliomas that were observed after surgical resection in order to understand tumor growth kinetics and the impact of molecular genetics. Results: Using log-linear mixed modeling, the entire cohort (n = 128) had a continuous %TVGR per 6 months of 10.46% [95% confidence interval (CI), 9.11%–11.83%] and a doubling time of 3.5 years (95% CI, 3.10–3.98). High molecular grade IDH-mt gliomas, defined by the presence of homozygous deletion of CDKN2A/B, had %TVGR per 6 months of 19.17% (95% CI, 15.57%–22.89%) which was significantly different from low molecular grade IDH-mt gliomas with a growth rate per 6 months of 9.54% (95% CI, 7.32%–11.80%; P < 0.0001). Using joint modeling to comodel the longitudinal course of TVGR and overall survival, we found each one natural logarithm tumor volume increase resulted in more than a 3-fold increase in risk of death (HR = 3.83; 95% CI, 2.32–6.30; P < 0.0001). Conclusions: TVGR may be used as an earlier measure of clinical benefit and correlates well with the WHO 2021 molecular classification of gliomas and survival. Incorporation of TVGR as a surrogate endpoint into future prospective studies of IDH-mt gliomas may accelerate drug development.